Physician profile
Gowrappala Ramesh
NPI 1053377051
$83,483.88
in general payments reported to CMS, 2019-2025
42 companies · $21K in 2025
The $21K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,007 · 2020: $1,368 · 2021: $8,535 · 2022: $1,921 · 2023: $3,035 · 2024: $40K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $11K · Travel and Lodging: $5,663 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,870.00 |
| Food and Beverage | $10,935.47 |
| Travel and Lodging | $5,662.73 |
| Education | $184.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $55,569.22 | 2024-2025 | Voquezna |
| Abbvie INC. | $7,550.77 | 2019-2025 | |
| Allergan, INC. | $5,366.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,960.88 | 2019-2025 | Entyvio, Gattex, Vpriv |
| Redhill Biopharma INC. | $2,137.80 | 2020-2023 | Talicia |
| Janssen Biotech, INC. | $1,288.36 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,123.77 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Gilead Sciences, INC. | $992.74 | 2019-2025 | Vemlidy |
| Celgene Corporation | $830.92 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $757.98 | 2019-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $585.80 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $536.21 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $499.65 | 2022-2025 | Ibsrela |
| Pfizer INC. | $414.93 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $340.98 | 2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $332.44 | 2023-2025 | Accrufer |
| Ironwood Pharmaceuticals, INC | $282.57 | 2020-2024 | Linzess |
| Aimmune Therapeutics, INC. | $254.18 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $243.31 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $196.52 | 2019-2024 | Resolution 360 Clip |
| Eisai INC. | $138.35 | 2020-2021 | |
| Romark Laboratories, Lc | $125.06 | 2020 | |
| Madrigal Pharmaceuticals | $118.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $109.73 | 2021-2023 | |
| Genzyme Corporation | $105.72 | 2023-2025 | |
| Evoke Pharma, INC. | $100.33 | 2020-2023 | Gimoti |
| Braintree Laboratories, INC. | $93.19 | 2021-2025 | Suflave, Sutab |
| Celltrion USA INC. | $71.31 | 2024 | Vegzelma, Zymfentra |
| Fujifilm Healthcare Americas Corporation | $41.12 | 2023 | Fujifilm |
| Baxter Healthcare | $40.00 | 2025 | |
| Alcresta Therapeutics, INC. | $37.52 | 2023 | Relizorb |
| Medtronic, INC. | $36.92 | 2023-2024 | Gi Genius |
| Exact Sciences Corporation | $35.77 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $29.63 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $28.42 | 2024 | Dificid |
| Mallinckrodt Hospital Products INC. | $26.44 | 2025 | Terlivaz |
| Shionogi INC | $23.63 | 2019 | |
| Vivus LLC | $20.84 | 2025 | Pancreaze |
| Biocon Biologics INC | $18.34 | 2024 | Hulio |
| Vibrant Gastro, INC. | $17.23 | 2023 | Vibrant Starter Kit |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gowrappala Ramesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.